Pfizer's Trading Volume Drops 25.43% to $997 Million Ranking 77th Amid $6 Billion Cancer Drug Deal

On May 21, 2025, Pfizer's trading volume reached $997 million, marking a 25.43% decrease from the previous day. This placed Pfizer at the 77th position in terms of trading volume for the day. Pfizer's stock price fell by 2.04%.

Pfizer has entered into a significant agreement with 3SBio to develop and market a cancer drug outside of China. This deal, valued at up to $6 billion, grants Pfizer exclusive rights to develop and sell the drug in markets beyond China. The agreement includes an upfront payment of $1.25 billion to 3SBio, with additional milestone payments of up to $4.8 billion.

BMO Capital has maintained its buy rating on Pfizer's stock following the announcement of the $6 billion cancer drug deal. This strategic move is expected to bolster Pfizer's oncology portfolio and enhance its market position in the global cancer treatment landscape.